The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCOS.L Regulatory News (COS)

  • There is currently no data for COS

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Positive results of ChondroMimetic Clinical Study

21 Feb 2018 07:00

RNS Number : 4560F
Collagen Solutions PLC
21 February 2018
 

 

21 February 2018

Collagen Solutions Plc

(the "Company")

 

Positive Eight-Year Results of ChondroMimetic® Cartilage Repair Clinical Study

 

Study confirms sustained long-term repair of knee cartilage and improved clinical symptoms

 

Collagen Solutions Plc (AIM: COS), the developer and manufacturer of medical grade collagen and tissue components for use in regenerative medicine, including orthopaedic, dental, wound care, and cardiovascular applications, announces successful results from an eight-year extension clinical study of 15 patients who received ChondroMimetic® implants as an osteochondral scaffold for the repair of cartilage defects in the knee. These positive results have now allowed Collagen Solutions to submit an initial submission for CE Mark.

Data highlights

· Quantitative 3D MRI analysis in the long-term study concluded that cartilage regeneration in the treated defects had reached a level and structural quality nearly identical to native cartilage.

· Improvement in patient clinical symptoms, including pain, function and activity level after treatment sustained over the eight-year period.

· The 'Knee Injury and Osteoarthritis Outcome Score' (KOOS), a well-known and validated patient reported outcome measure, showed outcomes following the ChondroMimetic® procedure were equal to or better than KOOS scores reported in the literature for substantially more expensive two-stage cartilage repair technologies.

Backed by these results ChondroMimetic® is positioned as the only minimally invasive, cost-effective, single-stage treatment that fits within surgeons' current surgical techniques for smaller cartilage defects with eight-year clinical effectiveness and repair quality data.

The market

There are over 1 million surgical procedures in the U.S. and Europe performed each year to treat cartilage defects of the knee1, yet current treatments have not demonstrated sustainable efficacy beyond five years post-treatment and/or have limited adoption due to cost and complexity. The current indication target for ChondroMimetic® is positioned to address at least 30%-40% of these surgeries once adopted world -wide.

 

 

Clinical results

The results of the ChondroMimetic® eight-year follow-up study demonstrated favorable improvement for clinical outcomes of pain, function and activity level. Specifically, patient reported scores from the "Modified Cincinnati Rating System" improved from 64.4 pre-operatively to 80.9, which was a highly statistically significant change (p=0.0065) and represented an 8-year overall grading of 'excellent'. Further the study reported KOOS scores for 5 subscales that were equal to or better than KOOS values reported in the literature for more expensive two-stage cartilage repair technologies (Saris AJSM 2008 and Saris AJSM 2014 respectively).

Advanced quantitative, 3D MRI analysis examined the tissue within the ChondroMimetic®-treated defects and found improved cartilage volume and tissue quality that was sustained through the 8-year follow-up. The extent of total defect filling was reported as an average of 95.1%, and repair tissue mean T2 relaxation time (a relative measure of tissue structure) was 52.5 ms, compared to 52.3 ms for the surrounding native cartilage in the same knees. These results demonstrate near complete filling of defects and regeneration of high-quality cartilage nearly indistinguishable from native cartilage.

Commenting on these clinical study results, Dr. László Hangody, orthopedic surgeon and the Principal Investigator for the study said: "Based on our first-hand clinical experience with ChondroMimetic® and these new results confirming the sustainability of both cartilage regeneration and the improvement in patient outcomes, it is my firm belief that this scaffold has an important place in the treatment of focal chondral lesions as an alternative to microfracture." Dr. Alan Getgood, orthopedic surgeon involved with ChondroMimetic's® early development, also commented: "The long term quantitative MRI data of cartilage repair volume and tissue quality in patients who were treated with ChondroMimetic® are extremely attractive. This is consistent with the previously performed animal studies which showed a 25% improvement in cartilage repair over controls."

The Company has made a presentation available regarding this study with further details on its website:

http://ir.collagensolutions.com/content/investors/presentations.asp 

Partnering opportunities

In December 2017, Collagen Solutions announced that it signed a license and distribution agreement with a South Korean industrial partner. The Company is in active discussions with potential multi-national partners and distributors, in anticipation of a European launch following CE Mark approval.

European regulatory clearance next steps

Collagen Solutions has started the submission process to re-establish the CE Mark for ChondroMimetic®. Following finalisation of the clinical study report, supplemental data will be submitted to complete the submission and support CE Mark approval, targeted for the second half of 2018.

Commenting on these positive results, Jamal Rushdy, CEO said: "This compelling data is a significant achievement in the decades-long effort by clinicians and scientists to develop a cost-effective and clinically effective treatment for these types of cartilage defects. We have illustrated the commercial opportunities with the announcement of an agreement with our South Korean partner in December last year. We look forward to announcing further key milestones including the granting of the CE Mark over the next few months. We are excited by ChondroMimetic's® progress and believe that Collagen Solutions is now in a period of solid progression which will provide future sustainable revenue generation."

 

Investor evening on 26 February 2018

As recently announced, on Monday 26 February Jamal Rushdy, CEO, will give an update to investors on ChondroMimetic® and in particular the significance of the most recent clinical data compared to current competitive procedures. Jamal will also summarise the key milestones expected this year for both ChondroMimetric® and the Company's core business activities. This event will also allow investors to meet Collagen Solutions' new CFO, Hilary Spence. The presentation will be filmed and the video will be available on the Company's website shortly afterwards at: http://ir.collagensolutions.com/content/investors/presentations.asp. For more information on the event please contact lisa.baderoon@collagensolutions.com or collagen@walbrookpr.com.

 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014

Collagen Solutions PlcJamal Rushdy, Chief Executive OfficerHilary Spence, Chief Financial OfficerLisa Baderoon, Head of Investor Relations

Tel: +44 (0) 141 648 9100Tel: +44 (0) 7721 413 496 or lisa.baderoon@collagensolutions.com

Cenkos Securities plc (NOMAD and Broker)Stephen KeysSteve Cox

Tel: +44 (0) 207 397 8900

Walbrook PRAnna DunphyHelen Cresswell

Tel: +44 (0) 20 7933 8780 or collagen@walbrookpr.comMob: +44 (0) 7876 741 001

 

About Collagen Solutions:

Collagen Solutions Plc is a global supplier, developer, and manufacturer of medical grade collagen, tissues, and related medical devices and components for use in regenerative medicine, medical devices and in-vitro diagnostics and research. The Company is also expanding its range of biomaterials-based finished medical devices based on its internal and acquired intellectual property for commercialisation with partners via licensing and distribution arrangements, including ChondroMimetic®. The Company's products are used in a wide variety of applications including orthopaedics, cardiovascular, dental, plastic surgery, wound healing, neurology and urology.

For more information go to: www.collagensolutions.com 

 

 


1 DRG Sports Medicine Devices US and Europe 2015

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RESKBLFLVLFLBBQ
Date   Source Headline
6th Nov 202010:08 amRNSHolding(s) in Company
27th Oct 202010:00 amRNSHolding(s) in Company
27th Oct 202010:00 amRNSHolding(s) in Company
23rd Oct 202011:32 amRNSResult of AGM
20th Oct 20205:30 pmRNSCollagen Solutions
20th Oct 20207:03 amRNSCollagen Solutions Acquired by Rosen’s Diversified
20th Oct 20207:03 amRNSRecommended cash offer for Collagen Solutions
20th Oct 20207:03 amRNSDirector/PDMR Shareholding
20th Oct 20207:03 amRNSAllotment of shares to employee benefit trust
20th Oct 20207:00 amRNSOFFER DECLARED UNCONDITIONAL IN ALL RESPECTS
9th Oct 20209:49 amRNSForm 8.5 (EPT/NON-RI)
6th Oct 20207:00 amRNSExtension of Offer and Acceptance Levels
2nd Oct 20208:30 amRNSForm 8.5 (EPT/NON-RI)
29th Sep 20209:36 amRNSForm 8.3 - [COLLAGEN SOLUTIONS PLC]
28th Sep 20209:11 amRNSForm 8.5 (EPT/NON-RI)
25th Sep 20201:02 pmRNSNotice of AGM
24th Sep 20208:32 amRNSForm 8.5 (EPT/NON-RI)
23rd Sep 202010:01 amRNSForm 8.5 (EPT/NON-RI)
18th Sep 20209:07 amRNSForm 8.5 (EPT/NON-RI)
17th Sep 20209:42 amRNSForm 8.3 - Collagen Solutions PLC
17th Sep 20208:29 amRNSForm 8.5 (EPT/NON-RI)
15th Sep 20201:04 pmRNSForm 8.3 - Collagen Solutions
15th Sep 20209:19 amRNSForm 8.5 (EPT/NON-RI)
14th Sep 202011:00 amRNSPosting of Offer Document
14th Sep 20209:13 amRNSForm 8.5 (EPT/NON-RI)
11th Sep 20209:20 amRNSForm 8.5 (EPT/NON-RI)
9th Sep 20203:53 pmRNSForm 8.3 - Collagen Solutions
9th Sep 202010:23 amRNSForm 8.5 (EPT/NON-RI)
8th Sep 20209:25 amRNSForm 8.3 - [COLLAGEN SOLUTIONS PLC]
7th Sep 20202:19 pmRNSForm 8.3 - Collagen Solutions
7th Sep 20209:40 amRNSForm 8.3 - [COLLAGEN SOLUTIONS PLC]
4th Sep 202011:27 amRNSForm 8.3 - Collagen Solutions
3rd Sep 20208:38 amRNSForm 8.5 (EPT/NON-RI)
2nd Sep 20204:30 pmRNSForm 8 (OPD) (Offeror - Rosen's Diversified, Inc.)
2nd Sep 20201:59 pmRNSForm 8.3 - Collagen Solutions
2nd Sep 202011:17 amRNSForm 8.3 - [COLLAGEN SOLUTIONS PLC]
2nd Sep 202010:23 amRNSForm 8.3 - [COLLAGEN SOLUTIONS PLC]
2nd Sep 20208:26 amRNSForm 8.5 (EPT/NON-RI)
1st Sep 20202:45 pmRNSForm 8.3 - Collagen Solutions plc
1st Sep 202012:48 pmRNSForm 8.3 - Collagen Solutions plc (Amendment)
1st Sep 202010:25 amRNSForm 8.3 - Collagen Solutions plc
1st Sep 20209:38 amRNSForm 8.3 - Collagen Solutions
1st Sep 20209:36 amRNSForm 8.3 - Collagen Solutions
1st Sep 20209:29 amRNSForm 8 (DD) - Collagen Solutions
1st Sep 20207:58 amRNSForm 8.5 (EPT/NON-RI)
28th Aug 20205:25 pmRNSForm 8 (DD) - Collagen Solutions
28th Aug 20203:27 pmRNSDirector/PDMR Shareholding
28th Aug 20201:34 pmGNWForm 8.3 - Collagen Solutions Plc [Amendment]
28th Aug 202010:24 amGNWForm 8.3 - Collagen Solutions Plc
28th Aug 20208:15 amRNSForm 8.5 (EPT/NON-RI)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.